111 related articles for article (PubMed ID: 32193881)
21. The utility of
Shell J; Tirosh A; Millo C; Sadowski SM; Assadipour Y; Green P; Patel D; Nilubol N; Kebebew E
Eur J Radiol; 2019 Mar; 112():130-135. PubMed ID: 30777201
[TBL] [Abstract][Full Text] [Related]
22. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin.
Binse I; Poeppel TD; Ruhlmann M; Ezziddin S; Görges R; Sabet A; Beiderwellen K; Bockisch A; Rosenbaum-Krumme SJ
J Nucl Med; 2016 Oct; 57(10):1512-1517. PubMed ID: 27033897
[TBL] [Abstract][Full Text] [Related]
23. CT diagnosis of unsuspected von Hippel-Lindau disease.
Kuhlman JK; Fishman EK; Marshall FF; Siegelman SS
Urology; 1987 Nov; 30(5):505-8. PubMed ID: 3672691
[TBL] [Abstract][Full Text] [Related]
24. Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy.
Graf R; Nyuyki F; Steffen IG; Michel R; Fahdt D; Wust P; Brenner W; Budach V; Wurm R; Plotkin M
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):68-73. PubMed ID: 22575489
[TBL] [Abstract][Full Text] [Related]
25. 68Ga-DOTATOC PET/CT Imaging in Solitary Fibrous Tumor of the Pleura.
Lococo F; Rapicetta C; Casali M; Bellafiore S; Rossi G; Treglia G; Gasparini E; Paci M
Clin Nucl Med; 2017 Jun; 42(6):e294-e296. PubMed ID: 28368890
[TBL] [Abstract][Full Text] [Related]
26. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
Schreiter NF; Brenner W; Nogami M; Buchert R; Huppertz A; Pape UF; Prasad V; Hamm B; Maurer MH
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):72-82. PubMed ID: 21927931
[TBL] [Abstract][Full Text] [Related]
27. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease.
Pulcrano M; Camera L; Pagano L; Del Vecchio S; Ferone D; Bodei L; Murgia A; Pace L; Storto G; Paganelli G; Colao A; Salvatore M; Lombardi G; Biondi B
J Endocrinol Invest; 2008 Apr; 31(4):352-9. PubMed ID: 18475055
[TBL] [Abstract][Full Text] [Related]
29. Clinical utility of
Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
[TBL] [Abstract][Full Text] [Related]
30. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
31. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
32. Intraindividual comparison of
Ouvrard E; Chevalier E; Addeo P; Sahakian N; Detour J; Goichot B; Bachellier P; Karcher G; Taïeb D; Imperiale A
Clin Endocrinol (Oxf); 2021 Jan; 94(1):66-73. PubMed ID: 32790887
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
[TBL] [Abstract][Full Text] [Related]
34. 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease.
Oosting SF; van Asselt SJ; Brouwers AH; Bongaerts AH; Steinberg JD; de Jong JR; Lub-de Hooge MN; van der Horst-Schrivers AN; Walenkamp AM; Hoving EW; Sluiter WJ; Zonnenberg BA; de Vries EG; Links TP
J Nucl Med; 2016 Aug; 57(8):1244-50. PubMed ID: 27173161
[TBL] [Abstract][Full Text] [Related]
35. 68Ga-DOTATOC-PET/CT-guided resection of a primary intraosseous meningioma: technical note.
Guinto-Nishimura GY; Gómez-Amador JL; Kerik-Rotenberg N; Uribe-Pacheco R; Sangrador-Deitos MV; Martínez-Manrique JJ
Neurosurg Focus; 2021 Jan; 50(1):E6. PubMed ID: 33386007
[TBL] [Abstract][Full Text] [Related]
36. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
Ruf J; Heuck F; Schiefer J; Denecke T; Elgeti F; Pascher A; Pavel M; Stelter L; Kropf S; Wiedenmann B; Amthauer H
Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582
[TBL] [Abstract][Full Text] [Related]
37. Humongous Seminal Vesicles on 68Ga-DOTATOC PET/CT: A Rare Presentation of a Neuroendocrine Tumor.
Hendriks RA; Hoogendoorn SP; van Gemert WAM; Kaal SEJ; Arens AIJ
Clin Nucl Med; 2020 Dec; 45(12):1003-1004. PubMed ID: 33031235
[TBL] [Abstract][Full Text] [Related]
38. The utility of
Jaiswal SK; Sarathi V; Malhotra G; Hira P; Shah R; Patil VA; Dalvi A; Prakash G; Lila AR; Shah NS; Bandgar T
J Pediatr Endocrinol Metab; 2021 Jan; 34(1):109-119. PubMed ID: 33180042
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience.
Thorwarth D; Henke G; Müller AC; Reimold M; Beyer T; Boss A; Kolb A; Pichler B; Pfannenberg C
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):277-83. PubMed ID: 21300465
[TBL] [Abstract][Full Text] [Related]
40. Incidental Detection of Retiform Hemangioendothelioma by 68Ga DOTATOC PET/CT.
Vadrucci M; Vandoni A; Gilardi L
Clin Nucl Med; 2017 Feb; 42(2):149-151. PubMed ID: 27997421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
